Tudor Investment Et Al Holding in Phototronics (PLAB) Trimmed by $398,832 as Stock Price Declined; Needelman Asset Management Has Decreased Abbott Laboratories (ABT) Position as Market Value Rose

April 21, 2018 - By Ellis Scott

Photronics, Inc. (NASDAQ:PLAB) Logo

Paul Tudor Jones decreased its stake in Phototronics Inc. (PLAB) by 81.02% based on its latest 2017Q4 regulatory filing with the SEC. Tudor Investment Corp Et Al sold 49,854 shares as the company’s stock declined 6.36% with the market. The hedge fund run by Paul Tudor Jones held 11,679 shares of the technology company at the end of 2017Q4, valued at $100,000, down from 61,533 at the end of the previous reported quarter. Tudor Investment Corp Et Al who had been investing in Phototronics Inc. for a number of months, seems to be less bullish one the $538.07 million market cap company. The stock decreased 0.65% or $0.05 during the last trading session, reaching $7.7. About 411,866 shares traded. Photronics, Inc. (NASDAQ:PLAB) has declined 25.69% since April 21, 2017 and is downtrending. It has underperformed by 37.24% the S&P500.

Needelman Asset Management Inc decreased its stake in Abbott Laboratories (ABT) by 20.59% based on its latest 2017Q4 regulatory filing with the SEC. Needelman Asset Management Inc sold 5,515 shares as the company’s stock rose 5.88% while stock markets declined. The institutional investor held 21,267 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $1.21 million, down from 26,782 at the end of the previous reported quarter. Needelman Asset Management Inc who had been investing in Abbott Laboratories for a number of months, seems to be less bullish one the $103.37B market cap company. The stock decreased 1.15% or $0.69 during the last trading session, reaching $59.19. About 5.87M shares traded. Abbott Laboratories (NYSE:ABT) has risen 34.85% since April 21, 2017 and is uptrending. It has outperformed by 23.30% the S&P500.

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 106 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Abbott Laboratories (NYSE:ABT) has “Hold” rating given on Thursday, August 31 by BMO Capital Markets. The rating was maintained by Argus Research on Friday, July 21 with “Buy”. Stifel Nicolaus maintained it with “Buy” rating and $71.0 target in Wednesday, January 24 report. The rating was downgraded by BTIG Research on Monday, January 22 to “Neutral”. On Wednesday, October 18 the stock rating was maintained by Cowen & Co with “Buy”. The rating was maintained by JP Morgan with “Overweight” on Thursday, January 25. The rating was maintained by RBC Capital Markets on Thursday, July 23 with “Outperform”. The firm has “Buy” rating by Jefferies given on Tuesday, September 5. The firm has “Buy” rating given on Wednesday, April 18 by Jefferies. The stock has “Hold” rating by BMO Capital Markets on Thursday, July 20.

Investors sentiment increased to 0.91 in Q4 2017. Its up 0.04, from 0.87 in 2017Q3. It is positive, as 52 investors sold ABT shares while 558 reduced holdings. 123 funds opened positions while 430 raised stakes. 1.22 billion shares or 0.64% more from 1.21 billion shares in 2017Q3 were reported. Buckingham Asset Management Ltd Liability Com holds 0.73% or 61,411 shares. Sva Plumb Wealth Mngmt Ltd Liability Co holds 30,261 shares. Monroe State Bank And Tru Mi holds 1,250 shares or 0.02% of its portfolio. Country Trust Commercial Bank holds 0.01% of its portfolio in Abbott Laboratories (NYSE:ABT) for 3,659 shares. 4,500 are owned by Peregrine Asset Advisers Incorporated. Capital Ltd Limited Company holds 0.02% in Abbott Laboratories (NYSE:ABT) or 1,122 shares. Chevy Chase stated it has 0.4% in Abbott Laboratories (NYSE:ABT). Needelman Asset invested 3.03% of its portfolio in Abbott Laboratories (NYSE:ABT). Morgan Stanley accumulated 8.33M shares. Thompson Davis Incorporated owns 0.13% invested in Abbott Laboratories (NYSE:ABT) for 1,000 shares. First Quadrant LP Ca holds 0.03% or 31,566 shares. Arrowstreet Partnership holds 26,800 shares. Evercore Wealth Management Ltd Liability holds 0.26% or 120,869 shares in its portfolio. Los Angeles Capital Mngmt Equity Incorporated, a California-based fund reported 255,448 shares. Intrust Natl Bank Na has 22,982 shares.

Since October 23, 2017, it had 1 insider buy, and 18 insider sales for $23.52 million activity. $58,635 worth of Abbott Laboratories (NYSE:ABT) shares were sold by Watkin Jared. 1,053 shares were sold by Bracken Sharon J, worth $62,056 on Wednesday, February 28. Fussell Stephen R sold $14.27 million worth of stock or 227,412 shares. MANNING JOSEPH J had sold 1,430 shares worth $84,344. Funck Robert E had sold 1,220 shares worth $71,970 on Wednesday, February 28. The insider Salvadori Daniel Gesua Sive sold 905 shares worth $53,369.

Among 7 analysts covering Photronics (NASDAQ:PLAB), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Photronics had 10 analyst reports since August 21, 2015 according to SRatingsIntel. The stock of Photronics, Inc. (NASDAQ:PLAB) earned “Hold” rating by Needham on Monday, September 18. The stock of Photronics, Inc. (NASDAQ:PLAB) earned “Buy” rating by Needham on Friday, December 4. On Friday, November 11 the stock rating was downgraded by Stifel Nicolaus to “Hold”. The firm earned “Buy” rating on Thursday, October 1 by Suntrust Robinson. Needham downgraded the shares of PLAB in report on Friday, November 11 to “Hold” rating. The firm earned “Buy” rating on Thursday, October 1 by SunTrust. RBC Capital Markets initiated the stock with “Buy” rating in Thursday, October 1 report. The stock of Photronics, Inc. (NASDAQ:PLAB) has “Buy” rating given on Friday, February 12 by Needham.

Since December 11, 2017, it had 1 insider purchase, and 9 insider sales for $4.09 million activity. Another trade for 110,000 shares valued at $841,500 was made by MACRICOSTAS CONSTANTINE S on Wednesday, February 21. 4,000 shares were sold by Burr Richelle E, worth $36,000. JORDAN JOHN P had bought 1,000 shares worth $8,500 on Friday, March 23. The insider TYSON MITCHELL G sold $8,840. FIEDEROWICZ WALTER M sold $49,590 worth of stock or 6,000 shares. Progler Christopher J had sold 3,750 shares worth $30,375 on Monday, April 2.

Investors sentiment decreased to 1.08 in Q4 2017. Its down 0.32, from 1.4 in 2017Q3. It dropped, as 24 investors sold PLAB shares while 50 reduced holdings. 38 funds opened positions while 42 raised stakes. 66.22 million shares or 3.60% more from 63.91 million shares in 2017Q3 were reported. Pacad Invest reported 0% stake. Rhumbline Advisers accumulated 0% or 161,980 shares. Hanson Doremus has invested 0.01% in Photronics, Inc. (NASDAQ:PLAB). Ahl Prns Llp stated it has 11,750 shares or 0% of all its holdings. Cortina Asset Management Ltd Liability stated it has 465,037 shares or 0.17% of all its holdings. Aqr Management Limited Liability Corporation holds 0.01% or 1.09 million shares in its portfolio. Da Davidson And invested 0.01% in Photronics, Inc. (NASDAQ:PLAB). Moreover, Gsa Capital Llp has 0.08% invested in Photronics, Inc. (NASDAQ:PLAB) for 157,684 shares. Hotchkis Wiley Mngmt Limited Liability Company has 176,746 shares for 0.01% of their portfolio. Ellington Mngmt Group Inc Lc invested in 0.03% or 22,300 shares. Perritt Cap Mgmt holds 469,450 shares. D E Shaw reported 0.01% of its portfolio in Photronics, Inc. (NASDAQ:PLAB). Amer Grp Inc Inc holds 53,411 shares or 0% of its portfolio. Numeric Ltd Limited Liability Company has invested 0% in Photronics, Inc. (NASDAQ:PLAB). 29,700 are owned by Louisiana State Employees Retirement Sys.

Analysts await Photronics, Inc. (NASDAQ:PLAB) to report earnings on May, 16. They expect $0.07 earnings per share, up 133.33% or $0.04 from last year’s $0.03 per share. PLAB’s profit will be $4.89M for 27.50 P/E if the $0.07 EPS becomes a reality. After $0.09 actual earnings per share reported by Photronics, Inc. for the previous quarter, Wall Street now forecasts -22.22% negative EPS growth.

Abbott Laboratories (NYSE:ABT) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>